Literature DB >> 2809196

IL-3 induces differentiation of bone marrow precursor cells to osteoclast-like cells.

B E Barton1, R Mayer.   

Abstract

IL-3, a cytokine with hematopoietic differentiating capability, induced murine bone marrow cells to differentiate into cells resembling osteoclasts. The cells resulting from treatment with IL-3 were multi-nucleated and demonstrated tartrate-resistant acid-phosphatase activity, as do resident osteoclasts found in bone. IL-3-induced osteoclast-like cell development in the absence of serum-derived vitamin D metabolites, and a mAb that inhibited IL-3-induced proliferation of an addicted cell line also inhibited the development of osteoclasts in the presence of IL-3. The same Ab had no effect on 1 alpha, 25-dihydroxyvitamin D3-induced differentiation of osteoclasts. This newly described function of IL-3 may indicate a role for activated T cells in the bone resorption seen with rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2809196

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.

Authors:  R Bataille; D Chappard; C Marcelli; P Dessauw; P Baldet; J Sany; C Alexandre
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

2.  Cytokines involved in the progression of multiple myeloma.

Authors:  F Merico; L Bergui; M G Gregoretti; P Ghia; G Aimo; I J Lindley; F Caligaris-Cappio
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

3.  Cloning and expression of a gene encoding an interleukin 3 receptor-like protein: identification of another member of the cytokine receptor gene family.

Authors:  D M Gorman; N Itoh; T Kitamura; J Schreurs; S Yonehara; I Yahara; K Arai; A Miyajima
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

Review 4.  Targeting the bone microenvironment in multiple myeloma.

Authors:  G David Roodman
Journal:  J Bone Miner Metab       Date:  2010-02-04       Impact factor: 2.626

Review 5.  Why clinicians should be interested in interleukin-3.

Authors:  P Valent; K Geissler; C Sillaber; K Lechner; P Bettelheim
Journal:  Blut       Date:  1990-12

6.  Acute side effects of homologous interleukin-3 in rhesus monkeys.

Authors:  F C van Gils; A H Mulder; C van den Bos; H Burger; R W van Leen; G Wagemaker
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

7.  Significant antitumor effect of a synthetic lipid A analogue, DT-5461, on murine syngeneic tumor models.

Authors:  E Kumazawa; A Tohgo; T Soga; T Kusama; Y Osada
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  Interleukin-3 plays dual roles in osteoclastogenesis by promoting the development of osteoclast progenitors but inhibiting the osteoclastogenic process.

Authors:  Huixian Hong; Zhenqi Shi; Ping Qiao; Hui Li; Erin M McCoy; Ping Mao; Hui Xu; Xu Feng; Shunqing Wang
Journal:  Biochem Biophys Res Commun       Date:  2013-10-05       Impact factor: 3.575

9.  Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption.

Authors:  E M Greenfield; S M Shaw; S A Gornik; M A Banks
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

Review 10.  Pathologic thrombopoiesis of rheumatoid arthritis.

Authors:  Ihsan Ertenli; Sedat Kiraz; M Akif Oztürk; Ibrahim c Haznedaroğlu; Ismail Celik; Meral Calgüneri
Journal:  Rheumatol Int       Date:  2003-02-11       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.